A 9-year-old girl with history of acute lymphoblastic leukemia (pre-B cell) presented with an acute onset left sided weakness. The brain MRI (Figure 1 ) revealed a DWI lesion with ADC correlate in the right parietal lobe. Over the next 24 hours her weakness progressed to involve the right side. A repeat MRI was done which revealed bilateral parietal lobe DWI lesions ( Figure 2 ). An MRA of head and neck was done and did not reveal any significant stenosis or occlusion. She had received intrathecal methotrexate one week prior to presentation. A working diagnosis of methotrexate induced neurotoxicity was made and she was treated with dextromethorphan. The next day her symptoms had nearly resolved and she was almost back to her baseline.
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Methotrexate related neurotoxicity is rare, but can develop from 5 to 14 days after treatment and symptoms may include headache, nausea, emesis, lethargy, altered mental status, blurred vision, aphasia, hemiparesis and seizures [1] . The MRI findings can include DWI lesions within cerebral deep white matter corresponding to the symptoms of hemiparesis. The contrast studies may not reveal any enhancement. 
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The treatment options include aminophylline, leucovorin [1] and dextrometharphan [2] . Methotrexate therapy is known to increase both plasma and CSF homocysteine which is directly toxic to vascular endothelium. In addition, methotrexate and its metabolites are excitatory agonists of the N-methyl-D-aspartate (NMDA) receptor. Dextromethorphan, a noncompetitive antagonist of NMDA receptor can help resolve the symptoms [2] .
